Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment by De Luca, Leonardo et al.
Address for correspondence: Leonardo De Luca, MD, PhD, FACC, FESC, Department of Cardiosciences; Division of  
Cardiology, A.O. San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152 Roma, Italy, tel: +39-06-58704419,  
e-mail: leo.deluca@libero.it; ldeluca@scamilloforlanini.rm.it
Received: 19.08.2020 Accepted: 13.02.2021 Early publication date: 9.04.2021
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Post-percutaneous coronary intervention angina: 
From physiopathological mechanisms  
to individualized treatment
Leonardo De Luca1, Giuseppe M.C. Rosano2, Ilaria Spoletini2
1Department of Cardiosciences, A.O. San Camillo Forlanini, Rome, Italy  
2Center for Clinical and Basic Research, Department of Medical Sciences,  
IRCCS San Raffaele Pisana, Rome, Italy
Abstract
Chronic ischemic heart disease (IHD) is a multifactorial disease with different underlying pathogenetic 
mechanisms. Percutaneous coronary intervention (PCI) is widely used in patients with IHD in order to 
reduce angina recurrence. However, after complete or incomplete revascularization procedures, patients 
may still present anginal symptoms, with a detrimental impact on quality of life and prognosis. 
This review summarizes the pathogenic mechanisms and the main challenges encountered in the diag-
nosis and management of post-PCI angina. (Cardiol J)
Key words: angina, ischemic heart disease, percutaneous coronary intervention,  
medical therapy, quality of life
Introduction
Ischemic heart disease (IHD) is the leading 
cause of death and disability for both sexes and its 
prevalence increases in an ageing population [1, 2]. 
The most frequent, and often the first manifestation 
of IHD, is chronic stable angina that affects approxi-
mately 112 million people worldwide [3, 4]. Besides 
pharmacological treatment, percutaneous coronary 
intervention (PCI) is widely used worldwide in 
IHD patients in order to reduce angina recurrence. 
However, up to 30% of IHD patients with stable 
angina continue experiencing symptoms despite 
treatment and revascularization procedures [5, 6].
Many post-PCI patients are burdened with 
recurrence of angina, impaired exercise capacity 
and quality of life. In fact, angina prevails over 
myocardial infarction (MI) and heart failure as 
a reason for impaired quality of life and disability [7]. 
Greater symptoms of physical limitation are strong-
ly predictive of secondary events and poorer sur-
vival, independently of other factors [7]. 
Finally, a common phenomenon is represented 
by readmissions following PCI. Indeed, approxi-
mately 25% of patients have unplanned readmis-
sions within 6 months [8]. This is due to sev-
eral factors, 44% of which are cardiac reasons [8]. 
Interestingly, angina and coronary artery disease 
(CAD) are the biggest contributors to the readmis-
sions due to cardiac reasons within 30 days and 
1 year after the index PCI [8]. Readmissions after 
PCI may be considered as an adverse outcome 
for the patient and an unnecessary cost for the 
healthcare system.
Taking into account all these issues, the pre-
sent reviews summarize the physiopathological 
mechanisms and the main challenges faced by 
patients with post-PCI angina, with a main focus on 
relapses of angina symptoms, choice of treatment 
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Recurrence of ischemia and angina  
in post-PCI patients
Figure 1 shows the incidence of angina recur-
rence after PCI in recent randomized clinical trials 
and international registries. In a study including 
more than 1000 stable angina patients evaluated 
with an exercise test after successful planned 
PCI, 29% still had an abnormal result at 1 month, 
which reached 31% of cases at 6 months [9]. Ac-
cordingly, meta-analyses of studies and registries 
in post-PCI patients demonstrated that, within 
1 year after successful PCI, the recurrence of 
angina ranges between 20% and 30% [10] and, 
within 3 years, angina persisted or reoccurred in 
up to 40% of cases, leading to higher healthcare 
costs [11]. Of note, a real-world analysis [11] on the 
clinical and economic burden associated with post-
PCI angina recurrence found that total healthcare 
costs in the first year after the index PCI were 
1.8 times greater for those with angina or chest 
pain compared to angina-free patients. 
Mechanisms underlying post-PCI angina recur-
rence are multiple and may include non-cardiovascu-
lar, cardiovascular non-coronary and coronary causes 
(Fig. 2). These latter may be functional and structural.
Functional mechanisms
Nowadays, functional reasons prevail over 
the structural ones and microvascular dysfunction 
is found in 64% of angina patients, in the absence 
of obstructive functionally significant epicardial 
Figure 1. Incidence of recurrent post-percutaneous 
coronary intervention angina according to main ran-
domized clinical trials (*) and registries (**); BVS — 
bioresorbable vascular scaffold; EES — everolimus-
-eluting stent; FFR — fractional flow reserve.
Figure 2. Cardiovascular and non-cardiovascular mechanisms of post-percutaneous coronary intervention angina 
recurrence; COPD — chronic obstructive pulmonary disease; HCM — hypertrophic cardiomyopathy; LV — left ven-
tricle; MI — myocardial infarction.



















Cardiology Journal 20XX, Vol. XX, No. X
stenosis, with a slightly superior prevalence of 
female sex [12]. Coronary artery vasospasm is also 
prevalent and is associated with silent myocardial 
ischemia, effort-induced angina and MI [12]. Simi-
larly, myocardial bridging, a congenital anomaly in 
which a segment of a coronary artery presents an 
intramuscular course under a “bridge” of overly-
ing myocardium, may cause vessel compression 
in systole, resulting in hemodynamic changes that 
may be associated with myocardial ischemia and 
angina [11].
Unfortunately, there is a paucity of data on the 
rate of functional reasons for ischemia along with 
epicardial stenosis due to an obsolete view that epi-
cardial stenosis was the main reason for ischemia 
and angina. Last but not least, another key patho-
physiological mechanism underlying symptoms and 
signs of myocardial ischemia, either in the pres-
ence or in the absence of an obstructive stenosis, 
is represented by myocardial cellular metabolic 
disturbances. The latter may cause ischemia and 
angina, even after removal of significant stenosis, 
further highlighting the need of a paradigm shift 
in stable IHD [13].
For all of these reasons, a functional evaluation 
is pivotal in PCI patients. There is evidence that 
a functional evaluation of coronary vasculature dur-
ing PCI is feasible and improves a post-PCI drug 
treatment approach, patients’ symptoms and qual-
ity of life [14]. As demonstrated by the Fractional 
flow reserve versus Angiography for Multivessel 
Evaluation (FAME 2) trial [15], routine measure-
ment of fractional flow reserve in patients with 
multivessel CAD who are undergoing PCI with 
drug-eluting stents significantly reduced the rate 
of the composite endpoint of death, nonfatal MI, 
and repeat revascularization at 1 year. Due to its 
long-term safety, fractional flow reserve guidance 
of multivessel PCI should be the standard of care, 
as also elucidated by the FAME 1 [16].
Structural mechanisms
Structural causes of post-PCI angina include 
in-stent restenosis, stent thrombosis, progres-
sion of atherosclerotic disease in other coronary 
segments and incomplete revascularization. The 
incidence of stent thrombosis and in-stent reste-
nosis, the two major causes of stent failure, has 
considerably been reduced in recent years by the 
introduction of new-generation drug-eluting stents 
[17]. Finally, it was investigated as to whether the 
type of stent influences frequency of angina after 
PCI. One study found no significant association 
between stent type and angina at 1 year after PCI 
[18]. Similarly, the A BioreSORBable vascular scaf-
fold versus drug-eluting stent in coronary disease 
(ABSORB) III trial [19] found no differences in 
adverse events at 1 year in CAD patients treated 
with an everolimus-eluting bioresorbable vascular 
scaffold, as compared with an everolimus-eluting 
cobalt-chromium stent.
Recurrence of angina due to the progression 
of coronary atherosclerosis in coronary segments 
different from those treated with PCI, it is also 
infrequent in the months after the procedure 
(only 5% of major adverse events were related 
to non-culprit lesions in the Providing Regional 
Observations to Study Predictors of Events in 
the Coronary Tree [PROSPECT] study at 1 year 
follow up [20]), even though it accounts for ap-
proximately half of recurrent coronary events. 
A more common scenario is currently represented 
by incomplete coronary artery revascularization 
(IR), with incidence rates ranging from 17% to 
85% in post-PCI patients [21, 22]. Such a huge 
variability is due to differences in study definitions 
of IR as well in the methodology used to analyse its 
frequency [23]. Regardless the type of revasculari-
zation, IR significantly impacts patient prognosis, 
increasing the risk of death, MI, repeated revas-
cularization, adverse events and lifestyle-limiting 
angina [23]. Predictors of IR are older age, pres-
ence of multiple comorbidities, complex coronary 
lesions, hyperlipidemia, total occlusion and number 
of diseased vessels [23]. As such, IR is considered 
a marker of complexity that allows the identifica-
tion of high-risk patients in whom medical therapy 
is therefore pivotal [24]. Of note, the Ranolazine 
in patients with Incomplete reVascularisation after 
Percutaneous Coronary Intervention (RIVER-PCI) 
study [25] aimed to prove the efficacy of ranolazine 
in about 2500 patients with IR after PCI. Although 
this trial confirmed that ischemia-driven events in 
patients with angina and incomplete revasculari-
zation following PCI are common (27% over 1.8 
years), it failed to prove prognostic benefits of the 
drug in this population [25]. However, there were 
significant improvements in the frequency of angina 
following PCI in both arms, with no differences 
between ranolazine vs. placebo at 1 month (86.6 
vs. 85.8, p = 0.62) or 12 months (88.4 vs. 88.5, 
p = 0.6). Patients with diabetes appeared to have 
a benefit with ranolazine for angina frequency at 
6 months (88.3 vs. 85.4, p = 0.033; p for interaction 
= 0.02). This difference, however, dissipated by 12 
months (p = 0.18). Notably, this trial had impor-
tant limitations since it included a mixed group of 
patients with IR, including untreated chronic total 
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occlusions and diffuse distal disease. In addition, 
the functional significance of untreated CAD was 
not routinely assessed.
Heart rate control in post-PCI  
angina patients 
Another key issue in post-PCI angina patients 
is poor control of heart rate (HR). It is well-known 
that resting HR has an important prognostic role 
[26], since it independently predicts total and 
cardiovascular mortality in angina patients. Even 
among patients treated with PCI, HR at discharge 
is a strong predictor of mortality [27]. As such, 
HR is a component of both ischemic and bleed-
ing risk scores. This is due to the role of HR in 
atherogenesis, atherosclerotic plaque formation 
and progression, and vascular remodeling [28]. 
Further, HR acts as a trigger of ischemia in patients 
with CAD [29]. Conversely, HR reduction leads to 
clinical benefits and, for this reason, lowering HR 
is a therapeutic target for angina [30].
The latest 2019 European Society of Cardiology 
guidelines for the management of chronic coronary 
syndromes (CCS) [2] continue recommending tar-
get levels of resting HR between 55 and 60 bpm. 
Unfortunately, the latest registries on CCS suggest 
poor control of resting HR in this population. For 
instance, in the prospeCtive observational Longi-
tudinAl RegIstry oF patients with stable coronary 
arterY disease (CLARIFY) registry [31], including 
more than 32,000 stable angina patients, 50% of the 
symptomatic angina patients had resting HR above 
70 bpm, in spite of the beta-blocker therapy, which 
was taken by 75% of the patients. In the same reg-
istry, HR above 70 bpm was associated with higher 
prevalence and severity of angina.
Choice of anti-anginal drugs/ 
/individualized treatment
Due to the multifactorial origin of IHD, in 
which different pathogenetic mechanisms may 
co-exist, leading to different clinical pictures with 
different predominances of symptoms over time 
[32], it is now been ascertained that patients need 
several anti-angina drugs in order to control symp-
toms, following a patient-oriented approach (Fig. 3). 
The choice of treatment should be related to the 
mechanisms causing angina, co-morbidities, po-
tential drug-interactions and tolerability. Thus, an 
individualized approach to angina treatment, the 
“Diamond” approach, which takes into consideration 
all these factors, has been proposed (Fig. 4) [32]. 
In particular, current first line anti-anginals, 
beta-blockers and calcium-channel blockers have 
not proven to have prognostic benefits (except for 
patients within 1 year after MI), as demonstrated 
by the CLARIFY study [33]. Further, recent meta-
-analyses found no evidence of superiority of one 
anti-angina class over another in reducing ischemia 
and angina [34].
The latest CCS guidelines [2] also acknowl-
edged the lack of evidence of superiority amongst 
the various anti-angina classes, and despite wheth-
er the line categorization is kept, they confirmed 
STEP 1. Beta-blocker*
STEP 2. On top a beta-blocker, or if a beta-blocker is
not tolerated, or resting HR still above 70–80 bpm
IVABRADINE
may be considered**






LONG-ACTING ORAL OR TRANSCUTANEOUS NITRATE
according to the identied cause of ischemia, 
patient prole and comorbidities
STEP 4: Myocardial revascularization
Figure 4. Combinations among classes of antianginal 
drugs according to the Diamond approach; *dihydro-
pyridines.
Figure 3. Flowchart of stable angina pectoris treatment; 
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the need of a patient tailored approach, endorsing 
the early use of the so called “second line drugs” 
along with the “first line drugs”, in order to provide 
adequate treatment according to the individual 
characteristics of the patient.
For all these reasons, more recent drugs with 
proven additional anti-anginal efficacy should be con-
sidered earlier in post-PCI symptomatic patients, 
along with the so called “first-line” anti-anginal 
drugs, given that the categorization of an antian-
ginal drug of first or second line is not confirmed 
[35]. Thus, ivabradine, trimetazidine and ranolazine 
should be considered, as described elsewhere [32].
Briefly, ivabradine was found to reduce symp-
toms and improve quality of life in a post-hoc 
analysis on angina patients with a history of revas-
cularization, who remained symptomatic in spite 
of an individually optimized dose of a beta-blocker 
[36]. A recent study [37] in patients with residual 
ischemia after PCI, demonstrated ivabradine ben-
efits on significant reduction of HR, lower incidence 
of angina during the stress test and improvements 
in functional capacity.
As for trimetazidine, it has proven benefits in 
patients with recurrent angina after PCI in spite 
of beta-blocker therapy such as preventing recur-
rence of angina, reducing restenosis, with a good 
safety profile [38].
Yet, it should be noted that some of these 
studies are single-center or open-label. The ef-
ficAcy and safety of Trimetazidine in patients with 
angina pectoris having been treated by Percutane-
ous Coronary Intervention (ATPCI) trial [39], was 
a randomized, multicenter, placebo controlled trial 
on more than 6000 post-PCI patients, which failed 
to demonstrate significant benefits of trimetazidine 
vs. placebo on the  primary efficacy endpoint, 
a composite of cardiac death, hospital admission for 
a cardiac event, recurrence or persistence of angina 
requiring other antianginal drugs or recurrence or 
persistence of angina requiring a coronary angio-
graphy.  However, it is important to underline that 
the ATPCI study was not designed to evaluate an-
tianginal properties of trimetazidine since patients 
included were asymptomatic and at low risk [39].
Optimization of anti-angina therapy 
Despite its importance, anti-anginal therapy is 
still often neglected in post-PCI angina patients. 
In the Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation (COUR-
AGE) trial [40], only 60% of the patients were on 
optimized medical therapy after PCI. In the Suivi 
d’une cohorte de patients COROnariens stables en 
région NORd-Pas-de-Calais (CORONOR) registry 
[41], the average number of anti-anginal drugs in 
post-PCI patients was rather low (mean: 1,4). In 
the recent International Study of Comparative 
Health Effectiveness with Medical and Inva-
sive Approaches (ISCHEMIA) trial [42], optimal 
medical therapy was prescribed, and risk factors 
control was obtained in more than 5000 patients 
with moderate to severe ischemia. The results 
demonstrated no superiority of PCI as an initial 
strategy on top of optimized medical therapy over 
optimized medical therapy alone. However, in the 
overall trial population, which included 35% of 
participants without angina at baseline, patients 
randomly assigned to the invasive strategy had 
greater improvement in angina-related health 
status than those assigned to the conservative 
strategy. The modest mean differences favoring 
the invasive strategy in the overall group reflected 
minimal differences among asymptomatic patients 
and larger differences among patients who had had 
angina at baseline [43].
It is even more striking that, in a study fol-
lowing post primary PCI patients [44], among the 
30% who reported angina within 6 weeks after 
the procedure, 68% remained treated only with 
beta-blocker, and did not receive a second anti-
anginal drug. 
Another main issue observed in clinical prac-
tice is the de-escalation of antianginal medications 
after PCI. There is evidence that down-titration is 
associated with an increased risk of angina recur-
rence and worsening of health status, particularly 
among patients with incomplete revascularization 
[23]. Interestingly, in the aforementioned RIVER-
-PCI study [25], 67% of the patients were taking 
0–1 anti-ischemic/angina drug in spite of the 
incomplete revascularization in parallel with the 
44% reporting daily or weekly angina after the 
procedure.
The STable Coronary Artery Diseases Reg-
isTry (START) study [45], a prospective, obser-
vational, nationwide study aimed to evaluate the 
presentation, management, treatment and quality 
of life of patients with stable CAD, revealed that 
treatment is still suboptimal in patients with an-
gina. Although angina patients more frequently 
received antianginal drugs compared to patients 
without angina, the combinations of angina relief 
drugs were rarely employed. 
Such an inadequate post-PCI anti-angina treat-
ment could be due to different reasons. First, from 
a socio-psychological point of view, the desire of 
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both healthcare professionals and patients to believe 
that the problem is solved may lead to some kind of 
inertia. Second, there are reasons linked to the health-
care system, such as the lack of systematic monitoring 
of symptoms after PCI. A German study [46] demon-
strated that 10% of ambulatory cardiologists did not 
ask patients about symptoms after PCI and 19% did 
not consider initiating drug therapy in angina patients 
with overruled significant coronary stenosis.
Third, a discrepancy between patient and 
doctor perceptions of burden of the disease may 
very often lead to under-recognition of angina. Up 
to 60% of the angina cases are not recognized by 
physicians in ambulatory practice, leading to lower 
rate of angina treatment up-titration [47].
A recent multinational European physician 
survey [48], on 659 general practitioners and car-
diologists evaluating more than 1900 stable angina 
patients, found a striking underestimation of the 
disease burden, especially in elderly, women, and 
those patients with a long-standing diagnosis (more 
than 2 years). Moreover, patients who previously 
had a PCI had more severe stable angina, despite 
more intense medical treatment, than patients 
without previous PCI.
All these data demonstrate that close monitor-
ing of stable angina patients and optimization of 
anti-angina therapy, even after a successful PCI, is 
mandatory in order to adequately treat symptoms 
and alleviate the disease burden. 
Conclusions
Recurrence of angina is a frequent and still 
neglected condition after contemporary PCI. His-
tory of symptoms, clinical examination and func-
tional imaging are essential to guide healthcare 
professionals in the search for possible underlying 
reasons for angina persistence and relapses in post-
-PCI patients. Optimizing anti-angina therapy is 
a necessary step, especially in absence of regional 
wall motion abnormalities. 
Thus, an efficacious and repeated monitoring may 
help improve post-PCI management in clinical practice 
and, also, may prevent an excessive and unnecessary 
use of PCI before optimizing medical therapy.
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